Literature DB >> 15843575

A CD8+ T cell heptaepitope minigene vaccine induces protective immunity against Chlamydia pneumoniae.

Irina Pinchuk1, Barry C Starcher, Brian Livingston, Amy Tvninnereim, Shiping Wu, Ettore Appella, John Sidney, Alessandro Sette, Benjamin Wizel.   

Abstract

An intact T cell compartment and IFN-gamma signaling are required for protective immunity against Chlamydia. In the mouse model of Chlamydia pneumoniae (Cpn) infection, this immunity is critically dependent on CD8(+) T cells. Recently we reported that Cpn-infected mice generate an MHC class I-restricted CD8(+) Tc1 response against various Cpn Ags, and that CD8(+) CTL to multiple epitopes inhibit Cpn growth in vitro. Here, we engineered a DNA minigene encoding seven H-2(b)-restricted Cpn CTL epitopes, the universal pan-DR epitope Th epitope, and an endoplasmic reticulum-translocating signal sequence. Immunization of C57BL/6 mice with this construct primed IFN-gamma-producing CD8(+) CTL against all seven CTL epitopes. CD8(+) T cell lines generated to minigene-encoded CTL epitopes secreted IFN-gamma and TNF-alpha and exhibited CTL activity upon recognition of Cpn-infected macrophages. Following intranasal challenge with Cpn, a 3.6 log reduction in mean lung bacterial numbers compared with control animals was obtained. Using a 20-fold increase in the Cpn challenging dose, minigene-vaccinated mice had a 60-fold reduction in lung bacterial loads, compared with controls. Immunization and challenge studies with beta(2)-microglobulin(-/-) mice indicated that the reduction of lung Cpn burdens was mediated by the MHC class I-dependent CD8(+) T cells to minigene-included Cpn CTL epitopes, rather than by pan-DR epitope-specific CD4(+) T cells. This constitutes the first demonstration of significant protection achieved by immunization with a CD8(+) T cell epitope-based DNA construct in a bacterial system and provides the basis for the optimal design of multicomponent anti-Cpn vaccines for humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15843575     DOI: 10.4049/jimmunol.174.9.5729

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Localization of the hypothetical protein Cpn0585 in the inclusion membrane of Chlamydia pneumoniae-infected cells.

Authors:  Jianhua Luo; Tianjun Jia; Youmin Zhong; Ding Chen; Rhonda Flores; Guangming Zhong
Journal:  Microb Pathog       Date:  2007-01-22       Impact factor: 3.738

2.  Pneumococcal capsular polysaccharide vaccine-mediated protection against serotype 3 Streptococcus pneumoniae in immunodeficient mice.

Authors:  Haijun Tian; Avi Groner; Marianne Boes; Liise-anne Pirofski
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

3.  Chlamydia pneumoniae inclusion membrane protein Cpn0585 interacts with multiple Rab GTPases.

Authors:  Claudio Cortes; Kimberly A Rzomp; Amy Tvinnereim; Marci A Scidmore; Benjamin Wizel
Journal:  Infect Immun       Date:  2007-10-01       Impact factor: 3.441

4.  Rapid In Vivo Assessment of Adjuvant's Cytotoxic T Lymphocytes Generation Capabilities for Vaccine Development.

Authors:  Darío Lirussi; Thomas Ebensen; Kai Schulze; Elena Reinhard; Stephanie Trittel; Peggy Riese; Blair Prochnow; Carlos A Guzmán
Journal:  J Vis Exp       Date:  2018-06-19       Impact factor: 1.355

Review 5.  Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines.

Authors:  Yinan Xiao; Hanyue Xu; Wen Guo; Yunuo Zhao; Yuling Luo; Ming Wang; Zhiyao He; Zhenyu Ding; Jiyan Liu; Lei Deng; Fushen Sha; Xuelei Ma
Journal:  Mol Biomed       Date:  2020-12-03

Review 6.  Role of CD8(+)T cells in the host response to Chlamydia.

Authors:  Benjamin Wizel; Johanna Nyström-Asklin; Claudio Cortes; Amy Tvinnereim
Journal:  Microbes Infect       Date:  2008-08-26       Impact factor: 2.700

7.  Host-Cell Survival and Death During Chlamydia Infection.

Authors:  Songmin Ying; Matthew Pettengill; David M Ojcius; Georg Häcker
Journal:  Curr Immunol Rev       Date:  2007

8.  The safety of two Bacillus probiotic strains for human use.

Authors:  Iryna B Sorokulova; Iryna V Pinchuk; Muriel Denayrolles; Irina G Osipova; Jen M Huang; Simon M Cutting; Maria C Urdaci
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

9.  Effect of age and vaccination on extent and spread of Chlamydia pneumoniae infection in C57BL/6 mice.

Authors:  Taylor Eddens; Sarah Beaudoin; Amanda Steinberger; C Scott Little; Dawn Shell; Benjamin Wizel; Brian Balin; Kerin L Fresa-Dillon
Journal:  Immun Ageing       Date:  2012-05-17       Impact factor: 6.400

10.  Protective immunity against lethal F. tularensis holarctica LVS provided by vaccination with selected novel CD8+ T cell epitopes.

Authors:  Shahar Rotem; Ofer Cohen; Erez Bar-Haim; Liat Bar-On; Sharon Ehrlich; Avigdor Shafferman
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.